Home / Stocks / Biofil Chem & Pharma Ltd
BIOFILCHEM

Biofil Chem & Pharma Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹30.26

Change

+0.54 (1.82%)

Open

₹29.58

Prev. Close

₹29.72

Day High

₹30.42

Day Low

₹29.58

Volume Analysis

Traded

6,708

Delivered

5,896

Delivery %

87.9%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹31.44 ₹30.93 ₹30.6 ₹30.09 ₹29.76 ₹29.25 ₹28.92
Fibonacci ₹30.93 ₹30.61 ₹30.41 ₹30.09 ₹29.77 ₹29.57 ₹29.25
Camarilla ₹30.49 ₹30.41 ₹30.34 ₹30.09 ₹30.18 ₹30.11 ₹30.03

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-8.25%

1 Week

-4.51%

1 Month

+2.51%

3 Months

+0.0%

6 Months

-4.75%

1 Year

-22.41%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Company Overview

Sector

Healthcare

Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.

TopFund Analysis

Biofil Chem & Pharma Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 50/100. The strongest factor is Corporate Governance (85/100), while Institutional Ownership (30/100) is the weakest area to weigh before deciding.

TopFund Score — Fundamentals Quality

50/100 — Average

Data confidence: 61/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Corporate Governance

85

Institutional Ownership

30

Risk & Volatility

31

Liquidity

50

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Certificate under Regulation 74(5) of the SEBI (Depository and Participants) Regulations, 2018 for the quarter ended 30th September, 2026

Trading window closed from 1 October 2026 ahead of Q2 FY26 unaudited results.

Source: BSE regulatory filings, via Screener.in.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 46.82% → 46.79%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 53.11% 53.08% 53.11% 53.1% 53.11% 53.11% 53.1% 53.12% 53.13% 53.12% 53.13% 53.13%
Promoters 46.82% 46.82% 46.82% 46.82% 46.82% 46.82% 46.82% 46.79% 46.79% 46.79% 46.79% 46.79%
FII 0.0% 0.03% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
DII 0.08% 0.08% 0.08% 0.08% 0.08% 0.08% 0.08% 0.08% 0.08% 0.08% 0.08% 0.08%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Biofil Chem & Pharma Ltd (this stock) — — — —
Sun Pharmaceutical Ind L 451,075 36.7 5.05 16.0%
Divi S Laboratories Ltd 294,139 86.1 16.34 16.5%
Torrent Pharmaceuticals L 177,632 81.8 9.67 27.4%
Apollo Hospitals Enter. L 125,893 55.6 11.86 21.5%
Laurus Labs Limited 125,380 93.6 20.73 18.3%
Zydus Lifesciences Ltd 118,693 26.2 4.27 21.2%

Which Mutual Funds Hold Biofil Chem & Pharma Ltd?

Frequently Asked Questions about Biofil Chem & Pharma Ltd

Community Sentiment

What are other investors saying about Biofil Chem & Pharma Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.